References
- Hess A D, Colombani P M. Mechanism of action: in vitro studies. Prog Allergy 1986; 38: 198–221
- Brynskov J, Freund L, Nørby Rasmussen S, et al. A placebo-controlled double-blind, randomized trial of cyclosporin therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845–850
- Malchow H, Ewe K, Brandes J W, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249–266
- Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–150
- Present D H, Korelitz B I, Wisch N, Glass J L, Sachar D B, Pasternack B S. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–987
- Best W R, Becktel J M, Singleton J W, Kern F, Jr. Development of Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
- van Hees P AM, van Elteren P H, van Lier H JJ, van Tongeren J HM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–286
- Harvey R F, Bradshaw J M. A simple index of Crohn's disease activity. Lancet 1980; 1: 514
- Siegel S, Castellan N J. Nonparametric statistics for the behavioural sciences, 2nd ed. McGraw-Hill, New York 1988; 110–111
- Winer B J. Statistical principles in experimental design, 2nd ed. McGraw-Hill, New York 1971; 855–859
- Rahe J J. Table of critical values for the Pratt matched pair signed ranked statistic. J Am Stat Ass 1974; 69: 368–373
- Siegel S, Castellan N J. Nonparametric statistics for the behavioural sciences, 2nd ed. McGraw-Hill, New York 1988; 184–189
- Brynskov J, Binder V, Riis P, et al. Low-dose cyclosporin in Crohn's disease: implications for clinical trials. Aliment Pharmacol Ther 1989; 3: 135–142
- Peltekian K M, Williams C N, MacDonald A S, Roy P D, Czolpinska E. Open trial of cyclosporine in patients with severe active Crohn's disease refractory to conventional therapy. Can J Gastroenterol 1988; 2: 5–11
- Allison M C, Pounder R E. Cyclosporin for Crohn's disease. Aliment Pharmacol Ther 1987; 1: 39–43
- Dieperink H. Cyclosporin A nephrotoxicity [Thesis]. Dan Med Bull 1989; 86: 235–248
- Mihatsch M J, Bach J F, Coovadia H M, et al. Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 1988; 66: 43–47
- Miescher P A, Favre H, Chatelanat F, Mihatsch M J. Combined steroid-cyclosporin treatment of chronic autoimmune diseases: clinical results and assessment of nephrotoxicity by renal biopsy. Klin Wochenschr 1987; 65: 727–736
- International kidney biopsy registry of cyclosporin A (Sandimmun) in autoimmune diseases. Kidney biopsies in control or cyclosporin A-treated psoriatic patients. Br J Dermatol 1990; 122(suppl 36)95–100
- Brynskov J, Thomsen H, Levin-Nielsen S. Reno-graphic monitoring of renal function in patients with Crohn's disease treated with low dose cyclosporin: a controlled study. Br Med J 1990; 300: 1438–1439
- Bendtzen K. Interleukin 1, interleukin 6 and tumour necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183–192
- Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 1989; 2: 177–189
- Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795–799
- Crabtree J E, Juby L D, Heatley R V, Lobo A J, Bullimore D W, Axon A TR. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990; 31: 1033–1036
- Mueller C, Knoflach P, Zielinski C C. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98: 639–646
- Ptachcinski R J, Venkataramanan R, Burckart G J. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107–132
- Ost L. Impairment of prednisolone metabolism by cyclosporin treatment in renal graft recipients. Transplantation 1987; 44: 533–535
- Ligumsky M, Simon P L, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease. Gut 1990; 31: 585–589
- Thomson A W, Neild G H. Cyclosporin: use outside transplantation. Br Med J 1991; 302: 4–5